stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Return on equity
NewAmsterdam Pharma Company N.V.'s return on equity over the twelve months to 30 September 2026 was −30.2%, down 1.9 percentage points from fiscal 2025 (−28.3%). Over the past ten years it has ranged from −49.5% (fiscal 2021) to 0.07% (fiscal 2020); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −28.3% | 17.91 |
| FY2024 | −46.2% | 3.05 |
| FY2023 | −49.3% | (38.57) |
| FY2022 | −10.7% | (10.68) |
| FY2022 | 0.00% | 49.46 |
| FY2021 | −49.5% | (49.46) |
| FY2021 | 0.00% | (0.07) |
| FY2020 | 0.07% | 0.00 |
| FY2020 | 0.07% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ADMA ADMA Biologics Inc compare | 42.0% |
| XNCR Xencor, Inc. compare | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement